PCK Reporter

April 15, 2014

Federal Court Dismisses Bell’s Motion to Disqualify the Law Firm of Bereskin and Parr in Patent Infringement Action

Mediatube Corp. and Northvu Inc v Bell Canada et al, 2014 FC 237 - The Court dismissed a motion to remove Bereskin & Parr as solicitors of record for Mediatube for a conflict of interest, finding that “[w]hile there may be some circumstances where related companies could be considered as one entity and one client, the circumstances in the present case do not lead to that conclusion.”
March 26, 2014

Federal Court Upholds Case Management Prothonotary’s Order Regarding Trial Date

Abbvie Corporation v Janssen Inc - 2014 FC 178 - The Court dismissed the appeal of the fixing of a trial date made by the Case Management Prothonotary.
March 21, 2014

FCA Upholds Trial Court Ruling that Availability of Compensation under s. 8 of the NOC Regulations Is a Question of Fact

Sanofi-Aventis Canada Inc v Teva Canada Limited - 2014 FCA 69 - The Court stated that whether there can be recovery for unauthorized indications under section 8 of the PM(NOC) Regulations is a question of fact, and that the purpose of section 8 damages is to compensate generics for a delay caused by NOC Proceedings.
March 21, 2014

Quebec Court Holds Non-Agents May Draft Patents, But Must Disclose Their Inability to File and Prosecute and any Potential Patentability Issues

Kirouac-Couture c ERL Étude et Recherche Inc, 2014 QCCQ 1405 - The Court held that ERL’s failure to provide the relevant disclosure vitiates Couture’s consent to enter the contract for preparation of the patent application.
March 21, 2014

FCA Upholds Rejection of Sanofi’s Motion to Amend Its Statement of Defence

Sanofi-Aventis Canada Inc v Teva Canada Limited - 2014 FCA 65 - The Court dismissed Sanofi’s appeal to amend its statement of defence in a PM(NOC) proceeding. It is not sufficient that allowing the amendment would not be unjust. What is required is that any injustice to the other party is capable of being compensated by an award of costs and the interest of justice must be served.
March 10, 2014

FCA Dismisses Pfizer’s Appeal Challenging Admissibility and Weight of Apotex Expert’s Testimony

Pfizer Canada Inc v Apotex Inc, 2014 FCA 54 - The Court rejected Pfizer's argument that the trial judge did not properly apply the R. v. J.-L.J., 2000 SCC 51 case when assessing the admissibility of what Pfizer alleged were novel scientific theories put forth by Apotex’s expert.
March 10, 2014

Federal Court of Appeal Upholds Disqualification, But Refuses to Invalidate Cobalt’s Notice of Allegation

Valeant Canada LP v Canada (Health), 2014 FCA 50 - The Court dismissed an appeal from the Federal Court’s decision to grant Valeant’s motion to disqualify Cobalt’s in-house lawyer from any further involvement in the application before the Court on the ground that he could be presumed to have Valeant’s confidential information.
February 18, 2014

Federal Court Holds Valeant’s Prohibition Application Is Not Abuse of Process

Valeant Canada LP v. Cobalt Pharmaceuticals – 2013 FC 1254 Cobalt moved, pursuant to s. 6(5)(b) of the PM(NOC) Regulations, to dismiss as an abuse of […]
February 11, 2014

Federal Court Adopts a More Restrained Approach to Construing Promise of the Celebrex Patent

Pfizer Canada Inc. v. Mylan Pharmaceuticals ULC – 2014 FC 38 In this case Pfizer brought a prohibition application under the PM(NOC) Regulations to prevent the […]
January 30, 2014

Commissioner’s Decision Upheld on Judicial Review

University of California v Commissioner of Patents [2014 FC 80]   Background The Applicant – University of California – sought judicial review pursuant to s. 18.1 […]